Gelteq shares surge 17.54% after-hours as preclinical study confirms 22% higher CBD bioavailability via proprietary oral gel platform.

Gelteq Limited (NASDAQ:GELS) surged 17.54% in after-hours trading following the release of preclinical study results on January 17, 2026, demonstrating its oral gel platform’s ability to enhance CBD bioavailability by 22% compared to conventional oil-based products. The findings position the company to accelerate market entry in Australia via the Special Access Scheme and expand globally, addressing key limitations of existing medicinal cannabis delivery methods. The study highlights the platform’s potential to improve patient outcomes through precise dosing, higher absorption efficiency, and a safer alternative to vaping, directly aligning with growing demand for innovative cannabinoid delivery solutions. This breakthrough underscores Gelteq’s competitive edge in the expanding medicinal cannabis sector, likely driving investor optimism and the sharp post-market rally.